Literature DB >> 24453053

Utilizing pharmacogenetics in psychiatry: the time has come.

David Durham1.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 24453053     DOI： 10.1007/s40291-014-0085-4

Source DB:  PubMed          Journal:  Mol Diagn Ther        ISSN： 1177-1062            Impact factor:   4.074


× No keyword cloud information.
  10 in total

1.  CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network.

Authors:  M V Relling; T E Klein
Journal:  Clin Pharmacol Ther       Date:  2011-01-26       Impact factor: 6.875

2.  Unintentional poisoning deaths--United States, 1999-2004.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2007-02-09       Impact factor: 17.586

3.  Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies.

Authors:  J Lazarou; B H Pomeranz; P N Corey
Journal:  JAMA       Date:  1998-04-15       Impact factor: 56.272

4.  Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness.

Authors:  W H Chou; F X Yan; J de Leon; J Barnhill; T Rogers; M Cronin; M Pho; V Xiao; T B Ryder; W W Liu; C Teiling; P J Wedlund
Journal:  J Clin Psychopharmacol       Date:  2000-04       Impact factor: 3.153

5.  Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality.

Authors:  D C Classen; S L Pestotnik; R S Evans; J F Lloyd; J P Burke
Journal:  JAMA       Date:  1997 Jan 22-29       Impact factor: 56.272

6.  Drug-drug interactions in a geriatric outpatient cohort: prevalence and relevance.

Authors:  Linda R Tulner; Suzanne V Frankfort; George J P T Gijsen; Jos P C M van Campen; Cornelis H W Koks; Jos H Beijnen
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

7.  Comparative mortality risk in adult patients with schizophrenia, depression, bipolar disorder, anxiety disorders, and attention-deficit/hyperactivity disorder participating in psychopharmacology clinical trials.

Authors:  Arif Khan; James Faucett; Shaneta Morrison; Walter A Brown
Journal:  JAMA Psychiatry       Date:  2013-10       Impact factor: 21.596

8.  The incident reporting system does not detect adverse drug events: a problem for quality improvement.

Authors:  D J Cullen; D W Bates; S D Small; J B Cooper; A R Nemeskal; L L Leape
Journal:  Jt Comm J Qual Improv       Date:  1995-10

9.  Psychiatric pharmacogenomics predicts health resource utilization of outpatients with anxiety and depression.

Authors:  J Winner; J D Allen; C Anthony Altar; A Spahic-Mihajlovic
Journal:  Transl Psychiatry       Date:  2013-03-19       Impact factor: 6.222

10.  Using a pharmacogenomic algorithm to guide the treatment of depression.

Authors:  D K Hall-Flavin; J G Winner; J D Allen; J J Jordan; R S Nesheim; K A Snyder; M S Drews; L L Eisterhold; J M Biernacka; D A Mrazek
Journal:  Transl Psychiatry       Date:  2012-10-16       Impact factor: 6.222
  10 in total
  1 in total

1.  Pharmacogenetics informed decision making in adolescent psychiatric treatment: a clinical case report.

Authors:  Teri Smith; Susan Sharp; Ann M Manzardo; Merlin G Butler
Journal:  Int J Mol Sci       Date:  2015-02-20       Impact factor: 5.923
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.